Molecular Templates found using ticker (MTEM) have now 7 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The target price ranges between 34 and 13 with a mean TP of 20.14. Now with the previous closing price of 9.67 this would imply there is a potential upside of 108.3%. The day 50 moving average is 9.36 and the 200 day MA is 11.37. The market capitalisation for the company is $534m. Find out more information at: http://www.mtem.com
Molecular Templates, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies. The company’s lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin’s lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted conditioning regimens to enhance the hematopoietic stem cell transplant process. Molecular Templates is headquartered in Austin, Texas.